Observation on efficacy and safety of DEB-TACE in the treatment of hepatocellular carcinoma
Objective To explore the efficacy and safety of drug-eluting beads transarterial chemoembolization(DEB-TACE)in the treatment of hepatocellular carcinoma.Methods 64 patients with hepatocellular carcinoma were divided into an observation group and a control group,with 32 cases in each group.The observation group received DEB-TACE treatment,and the control group received conventional transarterial chemoembolization(CTACE)treatment.Both groups were compared in terms of clinical effects,postoperative liver function indexes[albumin(ALB),alanine transaminase(ALT),aspartate transaminase(AST),total bilirubin(TBIL),direct bilirubin(DBIL)]and incidence of postoperative adverse reactions.Results The objective remission rate and disease control rate of the observation group were 68.75%and 93.75%,which were significantly higher than 43.75%and 75.00%of the control group(P<0.05).In the observation group,ALB,ALT,AST,TBIL and DBIL were(31.96±3.92)g/L,(140.82±38.17)U/L,(86.52±16.97)U/L,(35.12±8.28)μmol/L and(16.48±8.41)μmol/L.In the control group,ALB,ALT,AST,TBIL and DBIL were(32.82±3.67)g/L,(131.06±29.42)U/L,(78.16±18.59)U/L,(34.96±7.59)μmol/L and(17.43±9.15)μmol/L.There was no significant difference in postoperative ALB,ALT,AST,TBIL and DBIL between the two groups(P>0.05).There was no significant difference in the incidence of postoperative elevated blood pressure,fatigue,digestive tract reaction and fever between the two groups(P>0.05).Conclusion DEB-TACE has ideal in the treatment of hepatocellular carcinoma without increasing adverse reactions.It is safe and effective and is worth promoting.